본문 바로가기
KERD
논문KCI 등재

메타분석을 이용한 호르몬 수용체 양성/인체 상피세포 성장 인자 수용체 음성 진행성 유방암에서 사이클린 의존성 인산화효소 4/6 억제제와 방향화효소 억제제 병용요법과 방향화효소 억제제 단독요법의 임상적 유효성 및 안전성 비교 연구

A Comparative Study on the Clinical Efficacy and Safety between Combination Therapy with CDK 4/6 Inhibitor and AI Versus AI Monotherapy in HR+/HER type2- Advanced Breast Cancer: Updated Meta-analysis

조문경|손기호|백인환|김경|김민지
한국임상약학회 (Korean College Of Clinical Pharmacy)|2020.03|한국임상약학회지 (Korean Journal of Clinical Pharmacy)|제30권 제1호|pp. 1-10|DOI https://doi.org/10.24304/kjcp.2020.30.1.1

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

breast cancerMeta-analysisCDK 4/6 inhibitoraromatase inhibitor
주제분류약학

초록

Objective: The aim of the study was to perform a meta-analysis of randomized clinical trials to compare the clinical efficacy and safety between combination of cyclin-dependent kinase (CDK) 4/6 inhibitors with aromatase inhibitors (AIs) and AIs alone in patients with hormone receptor+/human epidermal growth factor receptor type2-(HR+/HER2-) advanced breast cancer. Methods: Published clinical studies were identified through electronic database searches until February 2019. Literature qualities were assessed by the Scottish Intercollegiate Guidelines Network Checklist. Key endpoints of efficacy were progression-free survival (PFS), objective response rate (ORR), and clinical benefit (CB). Endpoints of safety were adverse events (AEs) (neutropenia, leukopenia, any grade 3/ 4 AEs, and serious AEs) and on-treatment death. Meta-analysis was performed using the RevMan 5.3 software. Results: The selected five studies were evaluated as “good” in quality assessment. Compared to AIs alone, the combination therapy significantly improved PFS (pooled hazard ratio=0.55; 95% confidence interval (CI) 0.49-0.62), ORR (odds ratio=1.78; 95% CI=1.49-2.13), and CB (odds ratio=1.86; 95% CI=1.51-2.28). The prevalence of AEs was significantly higher in the combination group than in the AIs alone group. On-treatment death was greater in the combination group than in the AIs alone group, although insignificant. Conclusion: The combination therapy of CDK4/6 inhibitors with AIs was more effective for the treatment of HR+/HER2- advanced breast cancer, but less safe than AIs alone. The combination therapy should be effectively managed through patient monitoring, and further studies are needed to reduce AEs in the combination therapy of CDK4/6 inhibitors with AIs.

Abstract

Objective: The aim of the study was to perform a meta-analysis of randomized clinical trials to compare the clinical efficacy and safety between combination of cyclin-dependent kinase (CDK) 4/6 inhibitors with aromatase inhibitors (AIs) and AIs alone in patients with hormone receptor+/human epidermal growth factor receptor type2-(HR+/HER2-) advanced breast cancer. Methods: Published clinical studies were identified through electronic database searches until February 2019. Literature qualities were assessed by the Scottish Intercollegiate Guidelines Network Checklist. Key endpoints of efficacy were progression-free survival (PFS), objective response rate (ORR), and clinical benefit (CB). Endpoints of safety were adverse events (AEs) (neutropenia, leukopenia, any grade 3/ 4 AEs, and serious AEs) and on-treatment death. Meta-analysis was performed using the RevMan 5.3 software. Results: The selected five studies were evaluated as “good” in quality assessment. Compared to AIs alone, the combination therapy significantly improved PFS (pooled hazard ratio=0.55; 95% confidence interval (CI) 0.49-0.62), ORR (odds ratio=1.78; 95% CI=1.49-2.13), and CB (odds ratio=1.86; 95% CI=1.51-2.28). The prevalence of AEs was significantly higher in the combination group than in the AIs alone group. On-treatment death was greater in the combination group than in the AIs alone group, although insignificant. Conclusion: The combination therapy of CDK4/6 inhibitors with AIs was more effective for the treatment of HR+/HER2- advanced breast cancer, but less safe than AIs alone. The combination therapy should be effectively managed through patient monitoring, and further studies are needed to reduce AEs in the combination therapy of CDK4/6 inhibitors with AIs.

참고문헌 (29)

  1. Ferlay J, "Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136(5), pp.E359~E386 (2015)
  2. "SEER Cancer Stat Facts :Female Breast Cancer"[URL]
  3. Annual report of cancer statistics in Korea in 2015, "Korea Central Cancer Registry, National Cancer Center", Ministry of Health and Welfare, ~ (2017)
  4. Migliaccio I, "Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers", BMC Med, 13, pp.46~ (2015)
  5. Reinbolt RE, "Endocrine therapy in breast cancer: the neoadjuvant, adjuvant, and metastatic approach", Semin Oncol Nurs, 31(2), pp.146~155 (2015)
  6. Smith IE, "Aromatase inhibitors in breast cancer", N Engl J Med, 348(24), pp.2431~2442 (2003)
  7. Ramos-Esquivel A, "Cyclin-dependent kinase 4", 6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients : a systematic review and meta-analysis of phase III randomized clinical trials, 2018, pp.25(4), 479~488
  8. Hadji P, "Assessment of fracture risk in women with breast cancer using current vs emerging guidelines", Br J Cancer, 102(4), pp.645~650 (2010)
  9. O’Sullivan CC, "Overcoming endocrine resistance in hormonereceptor positive advanced breast cancer-the emerging role of CDK4", 6 inhibitors, 2015, pp.2(4), 029~
  10. Boyle F, "Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4", 6inhibitors on the current treatment paradigm, 2018, pp.14(Suppl 4), 3~
  11. "NCCN Clinical practice guidelines in oncology: Breast cancer Version3" (2015)[URL]
  12. "NCCN Clinical practice guidelines in oncology: Breast Cancer Version3" (2019)[URL]
  13. Finn RS, "Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1", TRIO-18, 2016, pp.18(1), 67~
  14. "Critical appraisal notes and checklists Methodology checklist2: randomised controlled trial"[URL]
  15. 최윤영, "제 2형 당뇨 환자에서 자가혈당측정의 임상적 유용성 : 체계적문헌고찰 및 메타분석", 한국임상약학회지, 20(3), pp.183~192 (2010), 한국임상약학회
  16. "Easy-to-understand cancer glossary"[URL]
  17. Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45(2), pp.228~247 (2009)
  18. "Common Terminology Criteria for Adverse Events (CTCAE) v4.0"[URL]
  19. Thill M, "Management of adverse events during cyclindependent kinase 4", 6(CDK4, Ther Adv Med Oncol, pp.2018, 10[DOI]
  20. Wallace BC, "Meta-Analyst:software for meta-analysis of binary, continuous and diagnostic data", BMC Med Res Methodol, 9, pp.80~ (2009)
  21. Hortobagyi GN, "Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer", Ann Oncol, 29(7), pp.1541~1547 (2018)
  22. Tripathy D, "Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3trial", Lancet Oncol, 19(7), pp.904~915 (2018)
  23. Johnston S, "MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer", NPJ Breast Cancer, 5, pp.5~ (2019)
  24. Finn RS, "Palbociclib and letrozole in advanced breast cancer", N Engl J Med, 375(20), pp.1925~1936 (2016)
  25. Baselga J, "Sorafenib in combination with capecitabine : an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer", J Clin Oncol, 30(13), pp.1484~1491 (2012)
  26. Keller AM, "Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer", J Clin Oncol, 22(19), pp.3893~3901 (2004)
  27. Yardley DA, "Efficacy and safety of ribociclib with letrozole in US patients enrolled in the MONALEESA-2 study", Clin Breast Cancer, 19(4), pp.268~277 (2019)
  28. Mukai H, "Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients", Int J Clin Oncol, 24(3), pp.274~287 (2019)
  29. Masuda N, "Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer : A Japanese phase II study", Cancer Sci, 109(3), pp.803~813 (2018)

관련 논문AI추천

Comparison of the Efficacy between First-Line Treatment Regimens for Patients with Hormone Receptor-Positive and HER2-Negative Metastatic Breast CancerChan Sub Park, Hyun-Ah Kim, In-Chul Park, Ji Yea Kim, Juhyeon Lee, Kwang Hyun Choi, Min Ki Seong, Na Won Kim, Sang Hee Kim, Woo Chul Noh한국유방암학회 · Journal of Breast Disease2021 · 제9권 제2호Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer김성배, 김정은, 안진희, 정경해, 정재호, 정혜현대한암학회 · Cancer Research and Treatment2022 · 제54권 제2호Real-World Clinical Data of Palbociclib in Asian Metastatic Breast Cancer Patients: Experiences from Eight Institutions박형순, 변재호, 신갑수, 양영준, 양지현, 우인숙, 원혜성, 이지은, 이희연, 전상훈, 홍지형대한암학회 · Cancer Research and Treatment2021 · 제53권 제2호Recent Developments in the Therapeutic Landscape of Advanced or Metastatic Hormone Receptor-Positive Breast Cancer이경훈, 이대원, 임석아, Eunice Yoojin Lee대한암학회 · Cancer Research and Treatment2023 · 제55권 제4호Efficacy of Combined Aromatase Inhibitor and Luteinizing Hormone- Releasing Hormone Agonist in Premenopausal Metastatic Breast CancerChan Sub Park, Hyun-Ah Kim, Jihye Choi, Min-Ki Seong, Sang Hee Kim, Woo Chul Noh한국유방암학회 · Journal of Breast Disease2018 · 제6권 제2호Targeting CDK4/6 in breast cancerArmand Jessica, Shanabag Anusha, Son Eugene, Yang Hee Won생화학분자생물학회 · Experimental and Molecular Medicine2025 · 제57권

이 간행물의 다른 논문 (7건)

고령 암환자에서의 nivolumab과 pembrolizumab의 유효성과 안전성 평가심미경, 김혜성, 정효근pp. 11-18국내 사람유두종바이러스백신 접종 후 자발적 이상반응 보고사례의 Brighton Collaboration 기준 활용 가능성 연구구현지, 이민택, 정선영, 박혜민, 유승훈, 강예진, 김묘송pp. 19-30HMG CoA-reductase inhibitors를 복용하는 환자의 잠재적 약물상호작용 연구이경주, 이유정, 유승완, 정예지, 남기남, 성재민, 김경림, 조세경, 이현윤pp. 31-35The Effects of Intrapatient Variability in Tacrolimus Concentration on Clinical Outcomes Immediately After Liver Transplantation김보람, 조재영, 유윤미, 김은지, Eunkyung Euni Lee, 조정원, 최영록, 이은숙, 이정화pp. 36-43타이로신키나아제 억제제의 임상적으로 유의한 약물상호작용 정보 일관성 분석안슬기, 아영미, 이주연pp. 44-50
원문 보기